Advertisement
Review Article| Volume 30, ISSUE 3, P667-676, September 2010

The Role of Second-Trimester Serum Screening in the Post–First-Trimester Screening Era

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Korenberg J.R.
        • Chen X.N.
        • Schipper R.
        • et al.
        Down syndrome phenotypes: the consequences of chromosomal imbalance.
        Proc Natl Acad Sci U S A. 1994; 91: 4997-5001
        • Mathews T.J.
        • Hamilton B.E.
        Mean age of mother, 1970–2000.
        Natl Vital Stat Rep. 2002; 51: 1-13
        • Egan J.F.
        • Benn P.
        • Borgida A.F.
        • et al.
        Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997.
        Obstet Gynecol. 2000; 96: 979-985
        • Martin J.A.
        • Hamilton B.E.
        • Sutton P.D.
        • et al.
        Births: final data for 2002.
        Natl Vital Stat Rep. 2003; 52: 1-113
        • National Vital Statistics Reports
        Centers for Disease Control and Prevention, Atlanta, GA.
        (Available at:) (Accessed May 30, 2010)
        • Odibo A.O.
        • Stamilio D.M.
        • Nelson D.B.
        • et al.
        A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.
        Obstet Gynecol. 2005; 106: 562-568
        • Cuckle H.
        • Benn P.A.
        Multi-marker maternal serum screening for chromosome abnormalities.
        in: Milunsky A. Milunsky J.A. Genetic disorders and the fetus. 6th edition. Wiley-Blackwell, Chichester2010: 771-818
        • ACOG Committee on Practice Bulletin
        ACOG practice bulletin NO.77: screening for fetal chromosomal abnormalities.
        Obstet Gynecol. 2007; 109: 217-227
        • Snijders R.J.
        • Noble P.
        • Sebire N.
        • et al.
        UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
        Lancet. 1998; 352: 343-346
        • Wald N.J.
        • Rodeck C.
        • Hackshaw A.K.
        • et al.
        First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
        Health Technol Assess. 2003; 7: 1-77
        • Malone F.D.
        • Canick J.A.
        • Ball R.H.
        • et al.
        First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER): principal results of the NICHD multicenter Down syndrome screening study.
        N Engl J Med. 2005; 353: 2001-2011
        • Merkatz I.R.
        • Nitowsky H.M.
        • Macri J.N.
        • et al.
        An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities.
        Am J Obstet Gynecol. 1984; 148: 886-894
        • Cuckle H.S.
        • Wald N.J.
        • Lindenbaum R.H.
        Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome.
        Lancet. 1984; 1: 926-929
        • Milunsky A.
        • Alpert E.
        Maternal serum AFP secreening.
        N Engl J Med. 1978; 298: 738-739
        • Crandall B.F.
        • Robinson L.
        • Grau P.
        Risks associated with an elevated maternal serum alpha-fetoprotein level.
        Am J Obstet Gynecol. 1991; 165: 581-586
        • Bogart M.H.
        • Pandian M.R.
        • Jones O.W.
        Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities.
        Prenat Diagn. 1987; 7: 623-630
        • Macri J.N.
        • Kasturi R.V.
        • Krantz D.A.
        • et al.
        Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin.
        Am J Obstet Gynecol. 1990; 163: 1248-1253
        • Lambert-Messerlian G.
        • Pinar H.
        • Rubin L.P.
        • et al.
        Second-trimester maternal serum markers in twin pregnancies with complete mole, report of 2 cases.
        Pediatr Dev Pathol. 2005; 8: 230-234
        • Paradinas F.J.
        • Sebire N.J.
        • Fisher R.A.
        • et al.
        Pseudo-partial moles, placental stem vessel hydrops and the association with Beckwith-Wiedemann syndrome and complete moles.
        Histopathology. 2001; 39: 447-454
        • Benn P.A.
        • Gainey A.
        • Ingardia C.J.
        • et al.
        Second trimester maternal serum analytes in triploid pregnancies, correlation with phenotype and sex chromosome complement.
        Prenat Diagn. 2001; 21: 680-686
        • Saller Jr., D.N.
        • Canick J.A.
        • Schwartz S.
        • et al.
        Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome.
        Am J Obstet Gynecol. 1992; 167: 1021-1024
        • Lambert-Messerlian G.M.
        • Saller Jr., D.N.
        • Tumber M.B.
        • et al.
        Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops.
        Prenat Diagn. 1998; 18: 1061-1067
        • Canick J.A.
        • Knight G.J.
        • Palomaki G.E.
        • et al.
        Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome.
        Br J Obstet Gynaecol. 1988; 95: 330-333
        • Kashork C.D.
        • Sutton V.R.
        • Fonda Allen J.S.
        • et al.
        Low or absent unconjugated estriol in pregnancy, an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis.
        Prenat Diagn. 2002; 22: 1028-1032
        • Bradley L.A.
        • Palomaki G.E.
        • Knight G.J.
        • et al.
        Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses.
        Am J Med Genet. 1999; 82: 355-358
        • Craig W.Y.
        • Haddow J.E.
        • Palomaki G.E.
        • et al.
        Major fetal abnormalities associated with positive screening test for Smith-Lemli-Opitz syndrome (SLOS).
        Prenat Diagn. 2007; 27: 409-414
        • Van Lith J.M.
        • Pratt J.J.
        • Beekhuis J.R.
        • et al.
        Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome.
        Prenat Diagn. 1992; 12: 801-806
        • Wallace E.M.
        • Grant V.E.
        • Swanston I.A.
        • et al.
        Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down's syndrome.
        Prenat Diagn. 1995; 15: 359-362
        • Brambati B.
        • Lanzani A.
        • Tului L.
        Ultrasound and biochemical assessment of first trimester pregnancy.
        in: Chapman M. Grudzinskas G. Chard T. The embryo: normal and abnormal development and growth. Springer-Verlag, New York1991: 181-194
        • Nicolaides K.H.
        • Azar G.
        • Byrne D.
        • et al.
        Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
        Br Med J. 1992; 304: 867-869
        • Snijders R.J.
        • Thom E.A.
        • Zachary J.M.
        • et al.
        First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique.
        Ultrasound Obstet Gynecol. 2002; 19: 353-359
        • Montenegro N.
        • Matias A.
        • Areias J.C.
        • et al.
        Increased fetal nuchal translucency, possible involvement of early cardiac failure.
        Ultrasound Obstet Gynecol. 1997; 10: 265-268
        • Fang Y.M.V.
        • Benn P.
        • Campbell W.
        • et al.
        Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists.
        Am J Obstet Gynecol. 2009; 201 (e1–5): 97
        • Benn P.A.
        • Egan J.F.
        Second trimester prenatal ultrasound and screening for Down syndrome.
        Prenat Diagn. 2007; 27: 884
        • Wald N.J.
        • Watt H.C.
        • Hackshaw A.K.
        Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.
        N Engl J Med. 1999; 341: 461-467
        • Canick J.A.
        • MacRae A.R.
        Second trimester serum markers.
        Semin Perinatol. 2005; 29: 203-208
        • Marteau T.M.
        • Kidd J.
        • Michie S.
        • et al.
        Anxiety, knowledge and satisfaction in women receiving false positive results on routine prenatal screening: a randomized controlled trial.
        J Psychosom Obstet Gynaecol. 1993; 14: 185-196
        • Wapner R.
        • Thom E.
        • Simpson J.L.
        • et al.
        First-trimester screening for trisomies 21 and 18.
        N Engl J Med. 2003; 349: 1405-1413
        • Cuckle H.
        • Benn P.
        • Wright D.
        Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters.
        Semin Perinatol. 2005; 29: 252-257
        • Benn P.
        • Donnenfeld A.E.
        Sequential Down syndrome screening: the importance of first and second trimester test correlations when calculating risk.
        J Genet Couns. 2005; 14: 409-413
        • Benn P.
        • Wright D.
        • Cuckle H.
        Practical strategies in contingent sequential screening for Down syndrome.
        Prenat Diagn. 2005; 25: 645-652
        • Gekas J.
        • Gagné G.
        • Bujold E.
        • et al.
        Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation.
        BMJ. 2009; 338: b138
        • Aagaard-Tillery K.M.
        • Malone F.
        • Nyberg D.
        • et al.
        Role of second-trimester genetic sonography after Down syndrome screening.
        Obstet Gynecol. 2009; 114: 1189-1196